Published: 28 January 2005 Orbital well-differentiated liposarcoma demonstrating chromosomal imbalances M Rosner, A Yosepovich, M Paul, N Rosen & M Perelman Eye 20, 126–128 (2006) Cite this article ...

Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study. A phase 1 study of MDM2 ...

A phase 3 trial to evaluate the efficacy and safety of milademetan (RAIN-32) began in late July, after Rain Therapeutics, Inc. announced the first patient with de-differentiated liposarcoma (DD LPS) ...

Patients and Tissues LS specimens were obtained at Dartmouth-Hitchcock Medical Center and M.D. Anderson Cancer Center between 1986 and 2012 under protocols approved by the Institutional Review ...

The results showed that 24 of 32 patients with de-differentiated liposarcoma and MDM2 amplification had stable disease and four other patients had partial responses for a disease control rate of ...

Background: Well-differentiated liposarcoma (WDLPS) and dedifferentiated liposarcoma (DDLPS) are common malignancies of adipocytic origin, which are in different differentiation stages. Both of them ...

To the Editor: In our opinion, the mass described as a myxoid liposarcoma and shown in the January 29 Images in Clinical Medicine1 is not an example of that entity but, rather, an atypical lipomat ...

Conversely, TIMP-4 presence was observed in normal fat cells and in the well-differentiated type of liposarcoma, leading the research team to conclude that the two molecules have opposite effects ...

Published Jul 20, 2021 8:00AM EDT The randomized, multi-center, open-label Phase 3 trial will evaluate the efficacy and safety of milademetan in patients with de-differentiated (DD) liposarcoma (LPS) ...

While there appears to be intratumor heterogeneity in hormone receptor expression, both between well- and de-differentiated areas of the same tumor, and over time within a patient's tumor (which ...